Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$1.00 +1.6%	$0.97	$0.69 ▼ $3.94	$198.20M	0.67	4.89 million shs	2.89 million shs
FBRX Forte Biosciences	$12.44 -3.8%	$9.33	$4.11 ▼ $28.68	$81.86M	2.85	171,181 shs	136,621 shs
GNFT GENFIT	$3.78 +1.6%	$4.12	$2.55 ▼ $6.42	$188.99M	1.15	10,501 shs	786 shs
INMB INmune Bio	$2.09 -9.5%	$7.32	$1.91 ▼ $11.64	$48.03M	1.55	734,425 shs	8.72 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	-0.93%	-5.35%	+15.22%	-30.18%	-55.66%
FBRX Forte Biosciences	+5.55%	+1.33%	+53.93%	+74.02%	+60,095.53%
GNFT GENFIT	+3.19%	-2.23%	-14.95%	+8.41%	+3.19%
INMB INmune Bio	-56.66%	-62.86%	-69.03%	-69.57%	-73.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.1342 of 5 stars	3.4	3.0	3.9	2.2	1.7	0.6
FBRX Forte Biosciences	3.0601 of 5 stars	3.5	4.0	0.0	2.5	1.7	0.6
GNFT GENFIT	2.2652 of 5 stars	3.5	4.0	0.0	2.7	0.0	0.0
INMB INmune Bio	1.6676 of 5 stars	3.4	0.0	0.0	2.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	600.00% Upside
FBRX Forte Biosciences	3.00	Buy	$61.00	390.35% Upside
GNFT GENFIT	3.00	Buy	$13.00	243.92% Upside
INMB INmune Bio	2.71	Moderate Buy	$22.80	990.91% Upside

Current Analyst Ratings Breakdown

Latest FBRX, GNFT, INMB, and ESPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/1/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $61.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.60	$0.02 per share	41.35	($1.97) per share	-0.51
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
GNFT GENFIT	$67.00M	2.82	$0.07 per share	51.61	$1.50 per share	2.52
INMB INmune Bio	$10K	4,802.82	N/A	N/A	$1.45 per share	1.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-149.15%	-114.25%	8/13/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)

Latest FBRX, GNFT, INMB, and ESPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
FBRX Forte Biosciences	N/A	5.22	5.22
GNFT GENFIT	0.08	1.23	1.23
INMB INmune Bio	N/A	2.64	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
FBRX Forte Biosciences	77.63%
GNFT GENFIT	2.24%
INMB INmune Bio	12.72%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
FBRX Forte Biosciences	5.90%
GNFT GENFIT	4.20%
INMB INmune Bio	35.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
INMB INmune Bio	10	22.98 million	14.78 million	Optionable

FBRX, GNFT, INMB, and ESPR Headlines

Recent News About These Companies

Alzheimer's trial misses goal, but subgroup result offers path forward

July 1 at 10:38 AM | thepharmaletter.comT

INmune Bio (NASDAQ:INMB) Lowered to "Neutral" Rating by BTIG Research

July 1 at 8:25 AM | marketbeat.com

INmune Bio (NASDAQ:INMB) Lowered to Sector Underperform Rating by Scotiabank

July 1 at 8:25 AM | marketbeat.com

Xpro phase II miss as Inmune’s Mindful tunes in to AD subgroup

July 1 at 5:37 AM | bioworld.comB

INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results

July 1 at 5:37 AM | finance.yahoo.com

INmune Bio fails to meet main goal in Alzheimer's treatment study

July 1 at 5:37 AM | msn.com

INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble

July 1 at 5:37 AM | finance.yahoo.com

INmune Bio slumps on midstage fail for Alzheimer's drug

July 1 at 5:37 AM | pharmaphorum.comP

INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial

July 1 at 5:37 AM | msn.com

INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low

July 1 at 5:37 AM | msn.com

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 30 at 4:05 PM | globenewswire.com

INmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trial

June 30 at 12:56 PM | proactiveinvestors.com

INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study

June 30 at 7:36 AM | reuters.com

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

June 30 at 7:30 AM | globenewswire.com

INmune Bio's US$24m Market Cap Fall Books Insider Losses

June 28 at 1:36 PM | finance.yahoo.com

INmune Bio Inc. (INMB) Stock Price Today - WSJ

June 28 at 3:34 AM | wsj.com

INmune Bio Stock Price, Quotes and Forecasts | NASDAQ:INMB - Benzinga

June 28 at 3:34 AM | benzinga.com

INmune Bio Stock (NASDAQ:INMB), Insider Trading Activity

June 27, 2025 | benzinga.com

INmune Bio Shares Pare Back Gains Following Direct Offering

June 27, 2025 | marketwatch.com

INmune Bio: Finding Pay Dirt In Alzheimer's?

June 27, 2025 | seekingalpha.com

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX, GNFT, INMB, and ESPR Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$1.00 +0.02 (+1.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 +0.00 (+0.50%)

As of 04:55 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Forte Biosciences NASDAQ:FBRX

$12.44 -0.49 (-3.79%)

Closing price 04:00 PM Eastern

Extended Trading

$12.56 +0.13 (+1.00%)

As of 04:42 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

GENFIT NASDAQ:GNFT

$3.78 +0.06 (+1.61%)

Closing price 03:56 PM Eastern

Extended Trading

$3.75 -0.03 (-0.77%)

As of 04:01 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

INmune Bio NASDAQ:INMB

$2.09 -0.22 (-9.52%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.03 (+1.53%)

As of 05:34 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time